ASOSIASI ANTARA AST DAN ALT PADA PASIEN COVID-19 DENGAN KOMORBID DAN NON KOMORBID DI KLINIK B KOTA TANGERANG TAHUN 2021
Abstract
Coronavirus Disease 19 (COVID-19) merupakan penyakit yang disebabkan oleh Novel Coronavirus (2019-nCoV) atau dinamakan SARS-CoV-2 yang merupakan virus jenis varian baru yang belum pernah diidentifikasi sebelumnya. Penelitian yang dilakukan oleh (Ponto et al., 2022) menyebutkan pada 90 pasien COVID-19 di labolatorium Rumah Sakit Umum Adhyaksa Jakarta menunjukkan 76,7% dengan rentang nilai 27-54 U/L pasien mengalami kenaikan SGOT/AST dan 77,8% dengan rentang 29-58 U/L pasien mengalami kenaikan SGPT/ALT. Penelitian ini bertujuan untuk mengetahui Asosiasi antara AST dan ALT pada pasien COVID-19 dengan Komorbid dan Non Komorbid Di Klinik B Kota Tangerang Tahun 2021 terhadap 70 pasien dengan menggunakan metode deskriptif analitik dengan pendekatan case control yang diambil dari data rekam medik. Hasil penelitian ini diperoleh, data pasien COVID-19 menunjukkan yang melakukan pemeriksaan berdasarkan jenis kelamin laki-laki sebanyak 39 orang (55,7%), dan perempuan sebanyak 31 orang (44,3%). Berdasarkan kelompok sampel hasil komorbid lebih dominan sebanyak 46 orang (65,7%) dibandingkan hasil non komorbid 24 orang (34,3%) dengan berdasarkan riwayat penyakit pada hipertensi lebih dominan sebanyak 29 orang (41,4%) dibandingkan diabetes Melitus sebanyak 17 orang (24,3%). Hasil uji Chi Square dan uji Fisher's Exact Test yaitu ada asosiasi antara kadar AST hari-1 dengan diperoleh (p=0,008), ada asosiasi antara kadar ALT hari-1 dengan diperoleh (p=0,044), ada asosiasi antara kadar AST hari-14 dengan diperoleh (p=0,020) dan tidak ada asosiasi antara kadar ALT hari-14 dengan diperoleh (p=0,543).
References
Coronavirus Disease 2019 (COVID-19) %7C Disease or Condition of the Week
%7C CDC.
Ekologi, J., Sains, M. and Masyarakat, P.C.- (2022) ‘Relevansi Pengetahuan
Dengan’, 3.
Fadillah, R., Nasrul, E. and Prihandani, T. (2020) ‘Artikel Penelitian Gambaran
Pemeriksaan Kadar SGOT , SGPT , Ureum dan’, Jurnal Kesehatan Andalas,
10(2), pp. 107–113.
Fan, Z. et al. (2020) ‘PANCREAS , BILIARY TRACT , AND LIVER Clinical Features
of COVID-19-Related Liver Functional Abnormality’, Clinical Gastroenterology and Hepatology, 18(7), pp. 1561–1566. Available at: https://doi.org/10.1016/j.cgh.2020.04.002.
Ganti, S. (2019) ‘No Title’, PASIEN, GAMBARAN AKTIVITAS ENZIM SGOT DAN
SGPT PADA BANGKINANG, HEPATITIS DI RSUD [Preprint]. Available at: http://repo.stikesperintis.ac.id/704/1/KTI.pdf.
Gunardi, W.D. (2021) ‘Pemeriksaan diagnosis laboratorium COVID-19’, Jurnal
Kedokteran Meditek, 27(2), pp. 173–182.
Gunawan, A., Prahasanti, K. and Utama, M.R. (2020) ‘PENGARUH KOMORBID
HIPERTENSI TERHADAP SEVERITAS PASIEN CORONAVIRUS DISEASE 2019’, 1(2), pp. 136–151.
Halawa Aristina (2021) ‘HUBUNGAN DUKUNGAN KELUARGA DAN STRATEGI
PENANGANAN’,HUBUNGAN DUKUNGAN KELUARGA DAN STRATEGI PENANGANAN KECEMASAN PADA PERAWAT YANG MERAWAT PASIEN PENDERITA COVID-19, 10(1), pp. 18–28.
Hasanah, D.Y. et al. (2020) ‘Gangguan Kardiovaskular pada infeksi COVID 19’,
Indonesian Journal of Cardiology, 41(2), pp. 59–68. Available at: https://doi.org/10.30701/ijc.994.
Hwaiz, R. et al. (2020) ‘Since January 2020 Elsevier has created a COVID-19
resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information ’, (January).
Jumei, M. (2018) ‘Gambaran kadar enzim serum glutamic oxaloacetic transminase
(SGOT) pada mahasiswa obesitas di poltekkes kemenkes kendari karya tulis ilmiah’, Politeknik Kesehatan Kendari, pp. 1–56.
Kemenkes RI (2020) ‘Halaman Sampul’, Pedoman pencegahan dan pengendalian
Coronavirus Disease (COVID_19), 9(2), pp. 1–214. Available at: https://doi.org/10.29239/j.agrikan.9.2.i-iii.
Larasati, D. (2021) ‘Peningkatan Informasi Penyakit dengan Komorbid Hipertensi
pada Masa Pandemi Covid-19 di Puskesmas Piyungan’, Jurnal Abdimas Madani, 3(1), pp. 21–25.
Li, L. quan et al. (2020) ‘COVID-19 patients’ clinical characteristics, discharge rate,
and fatality rate of meta-analysis’, Journal of Medical Virology, 92(6), pp. 577–583. Available at: https://doi.org/10.1002/jmv.25757.
Marfilan, D.R. et al. (2021) ‘The Correlation of Transaminase Enzymes on the
Prognosis of Covid-19 Patients in the ICU Infection Center Dr. Wahidin Sudirohusodo General Hospital Makassar’, Britain International of Exact Sciences (BIoEx) Journal, 3(3), pp. 182–196. Available at: https://doi.org/10.33258/bioex.v3i3.501.
Mathematics, A. (2016) Komorbid dan Non Komorbid pada pasien COVID-19, pp. 1–23.
Mitra, P. et al. (2020) ‘Association of Comorbidities with Coronavirus Disease 2019:
A Review’, Annals of the National Academy of Medical Sciences (India), 56(02), pp. 102–111. Available at: https://doi.org/10.1055/s-0040-1714159.
Mus, R. et al. (2021) ‘Studi Literatur: Tinjauan Pemeriksaan Laboratorium pada
Pasien COVID-19’, Jurnal Kesehatan Vokasional, 5(4), p. 242. Available at: https://doi.org/10.22146/jkesvo.58741.
Nanda, S. and Murtiani, F. (2021) ‘Kematian pada Pasien COVID-19 Berdasarkan
Komorbid dan Tingkat Keparahan Death In COVID-19 Patients Based On
Comorbid And Severity’, 8(1), pp. 44–54.
Nasution, D. (2022) ‘Gambaran Kadar Enzim Aspartat Aminotransferase (Ast) Dan
Enzim Alanin Aminotransferase (Alt) Pada Pasien Penderita Sirosis Hati Di Rumah Sakit Efarina Etaham Berastagi’, Jurnal Ilmiah Multidisiplin, 1(5), pp. 992–996.
Ndera, M.L., Supriyatni, N. and Rahayu, A. (2021) ‘Faktor Komorbid terhadap
Covid-19 di Puskesmas Kota Tahun 2020’, Jurnal Biosainstek, 3(2), pp. 1–9. Available at: https://doi.org/10.52046/biosainstek.v3i2.723.
Pondaag, F., Moeis, E. and Waleleng, B. (2014) ‘Gambaran Enzim Hati Pada
Dewasa Muda Dengan Obesitas Sentral’, e-CliniC, 2(2). Available at: https://doi.org/10.35790/ecl.2.2.2014.5101.
Ponto, C.V.I., Rambert, G.I. and Wowor, M.F. (2022) ‘Description of SGOT and
SGPT Levels in Pregnant Women with Confirmed COVID-19’, Medical Scope Journal, 3(2), p. 134. Available at: https://doi.org/10.35790/msj.v3i2.37836.
Rahayu, L.A. et al. (2021) ‘Hipertensi, Diabetes Melitus Dan Obesitas Sebagai
Faktor Komorbiditas Utama Terhadap Mortalitas Pasien Covid-19 : Sebuah Studi Literatur Tijauan Pustaka Hypertension , Diabetes Mellitus , and Obesity As the Main Comorbidity Factors of Mortality in Covid-1’, Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 9, pp. 90–97.
Rosida, A. (2016) ‘Pemeriksaan Laboratorium Penyakit Hati’, Berkala Kedokteran,
12(1), p. 123. Available at: https://doi.org/10.20527/jbk.v12i1.364.
Sari, S.R. and Kurniawan, J. (2022) ‘Pengaruh Gangguan Fungsi Hepar terhadap
Prognosis Pasien COVID-19’, Jurnal Penyakit Dalam Indonesia, 9(1), p. 42. Available at: https://doi.org/10.7454/jpdi.v9i1.624.
Suryaputra, G.P., Apriningsih, H. and Wardani, M.M. (2022) ‘Hubungan Komorbid
dengan Mortalitas dan Lama Rawat Inap pada Pasien COVID-19 di Rumah Sakit UNS Surakarta’, Plexus Medical Journal, 1(1), pp. 32–41. Available at: https://doi.org/10.20961/plexus.v1i1.20.
Tandra, P.D.H. (2021) VIRUS CORONA BARU COVID-19: Kenali, Cegah, Lindungi
Diri Sendiri \& Orang Lain. Rapha Publishing. Available at: https://books.google.co.id/books?id=-7AfEAAAQBAJ.
WHO (2019) Global research on coronavirus disease (COVID-19) Available at:
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov.
Wibowo dr. Bambang, drg. Saraswati MPH and Sinaga dr. Ganda (2020) ‘Petunjuk
Teknis Pelayanan Puskesmas Pada Masa Pandemi COVID-19’, Petunjuk Teknis Pelayanan Puskesmas Pada Masa Pandemi COVID-19, 108(Direktorat Jenderal Pelayanan Kesehatan, Kementerian Kesehatan RI), pp. 3–3.
Wu, Z. and McGoogan, J.M. (2020) ‘Characteristics of and Important Lessons From
the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.’, JAMA, 323(13), pp. 1239–1242. Available at: https://doi.org/10.1001/jama.2
Copyright (c) 2023 IFI Cabang Kota Bekasi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Submission Preparation Checklist
As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
- I hereby declare that this submission is my own work.
- I hereby stated that this manusrcipt have no plagiarism matter.
- I declare the submission has no potential conflict of interest.
- I hereby stated that this manusrcipt have never been previously published in any other scientific publication and not being under reviewing process of any other scientific publication.
- The submitted manuscript contains no least than 2.000 words and not exceed 25 pages A4 including figures and tables, without any appendixes.
- The submitted manuscript has been written using Open Office Text Document (.odt) or Microsoft Word (.doc/.docx).
- Title already brief and concise, written in English, and less than 15 words.
- Abstract already brief and concise and not exceed 150 words in English.
- Keywords are written in English, between three to five phrase.
- The manuscript structure already consist: Introduction, Method/Material, Result and Discussion, Conclusion, Acknowledgement, and References.
- References are written according the writing style of MEV. The primary references are no less than 80% from at least fifteen sources and had been taken from the late ten year publications.
- The instructions in Ensuring a Blind Review have been followed to the submitted manuscript.
- (At least) two scientific referees have been suggested in "Comments for the Editor" textbox in the bottom of this page.
Copyright Notice
Retained Rights/Terms and Conditions of Publication
1. As an author you (or your employer or institution) may do the following:
- make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use;
- make copies and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g. via an e-mail list or list server);
- present the article at a meeting or conference and to distribute copies of the article to the delegates attending such meeting;
- for your employer, if the article is a ‘work for hire’, made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g. training);
- retain patent and trademark rights and rights to any process, procedure, or article of manufacture described in the article;
- include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially);
- use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal); and prepare other derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal;
- may reproduce or authorize others to reproduce the article, material extracted from the article, or derivative works for the author’s personal use or for company use, provided that the source and the copyright notice are indicated, the copies are not used in any way that implies RCEPM-LIPI endorsement of a product or service of any employer, and the copies themselves are not offered for sale.
All copies, print or electronic, or other use of the paper or article must include the appropriate bibliographic citation for the article’s publication in the journal.
2. Requests from third parties
Although authors are permitted to re-use all or portions of the article in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use. Requests for all uses not included above, including the authorization of third parties to reproduce or otherwise use all or part of the article (including figures and tables), should be referred to RCEPM-LIPI by going to our website athttp://telimek.lipi.go.id.
3. Author Online Use
- Personal Servers. Authors and/or their employers shall have the right to post the accepted version of articles pre-print version of the article, or revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on their own personal servers or the servers of their institutions or employers without permission from RCEPM-LIPI, provided that the posted version includes a prominently displayed RCEPM-LIPI copyright notice and, when published, a full citation to the original publication, including a link to the article abstract in the journal homepage. Authors shall not post the final, published versions of their papers;
- Classroom or Internal Training Use. An author is expressly permitted to post any portion of the accepted version of his/her own articles on the author’s personal web site or the servers of the author’s institution or company in connection with the author’s teaching, training, or work responsibilities, provided that the appropriate copyright, credit, and reuse notices appear prominently with the posted material. Examples of permitted uses are lecture materials, course packs, e-reserves, conference presentations, or in-house training courses;
- Electronic Preprints. Before submitting an article to an MEV Journal, authors frequently post their manuscripts to their own web site, their employer’s site, or to another server that invites constructive comment from colleagues. Upon submission of an article to MEV Journal, an author is required to transfer copyright in the article to RCEPM-LIPI, and the author must update any previously posted version of the article with a prominently displayed RCEPM-LIPI copyright notice. Upon publication of an article by the RCEPM-LIPI, the author must replace any previously posted electronic versions of the article with either (1) the full citation to the work with a Digital Object Identifier (DOI) or link to the article abstract in MEV journal homepage, or (2) the accepted version only (not the final, published version), including the RCEPM-LIPI copyright notice and full citation, with a link to the final, published article in journal homepage.
4. Articles in Press (AiP) service
RCEPM-LIPI may choose to publish an abstract or portions of the paper before we publish it in the journal. Please contact our Production department immediately if you do not want us to make any such prior publication for any reason, including disclosure of a patentable invention.
5. Author/Employer Rights
If you are employed and prepared the article on a subject within the scope of your employment, the copyright in the article belongs to your employer as a work-for-hire. In that case, RCEPM-LIPI assumes that when you sign this Form, you are authorized to do so by your employer and that your employer has consented to the transfer of copyright, to the representation and warranty of publication rights, and to all other terms and conditions of this Form. If such authorization and consent has not been given to you, an authorized representative of your employer should sign this Form as the Author.
6. RCEPM-LIPI Copyright Ownership
It is the formal policy of RCEPM-LIPI to own the copyrights to all copyrightable material in its technical publications and to the individual contributions contained therein, in order to protect the interests of the RCEPM-LIPI, its authors and their employers, and, at the same time, to facilitate the appropriate re-use of this material by others. RCEPM-LIPI distributes its technical publications throughout the world and does so by various means such as hard copy, microfiche, microfilm, and electronic media. It also abstracts and may translate its publications, and articles contained therein, for inclusion in various compendiums, collective works, databases and similar publications
Every accepted manuscript should be accompanied by "Copyright Transfer Agreement" prior to the article publication.